Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UZY
|
|||
| Former ID |
DIB011763
|
|||
| Drug Name |
Lpathomab
|
|||
| Synonyms |
Anti-lysophosphatidic acid (LPA) monoclonal antibody (cancer/neuropathic pain/fibrosis/ocular inflammation), Lpath
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Lpath Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02341508) A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab inSubjects With Neuropathic Pain. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.